Lonza

Few pharmaceuticals players in Europe match the executional depth of Lonza. From Basel, the group manages a workforce of approximately 18k and generates close to $7B in revenue, while steadily widening the gap with regional peers.

Recent strategic moves point to a deliberate pivot toward higher-margin segments, where pricing power and brand equity matter more than pure volume.

“Lonza is, in its category, exactly the kind of compounding regional champion the next decade of capital allocation will reward.”

Analysts increasingly view the group as a regional bellwether — its quarterly trajectory tends to anticipate sector-wide moves.